Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib and Rituximab in Marginal Zone Lymphoma Patients
NCT03474744Phase 2Active, not recruiting
- Start
- Dec 2019
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of copanlisib in marginal zone lymphoma (MZL). Started Dec 2019; status: active, not recruiting.
02
Drugs
copanlisib
03
Conditions
marginal zone lymphoma (MZL)
Beyond the preview
Go deeper on NCT03474744.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03474744.